osimertinib
astrazeneca
['adaura']
 these data look vy good. however, i expect os curve for osi will deteriorate w/delay after 3 yr rx interval ends, just as in all other adjuvant egfr tki trials &amp; dfs curve on adaura. also, if nearly all pts on ctrl arm didn't get osi at relapse, it's test of access, not timing.
Med Onc,@CityofHope; VP Netwk Strategy AccessHope, Founder,@CancerGRACE; Web Ed,@JAMAOnc; Author/Ed, @UptoDate

Telemed/digital med fan. 
Disclosures @ website